Palmer, T. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland : retrospective population study :
[անգլ.] / T. Palmer, L. Wallace, K. G. Pollock … [et al.] // BMJ : журн. — 2019. — Vol. 365. — L1161. — doi:10.1136/bmj.l1161. — PubMed. — PMC6446188.
«FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus». FDA. 2006-06-08. [4]Արխիվացված 2009-05-12 Wayback Machine. Retrieved on 2007-02-04.
Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ (2006). «HPV-mediated cervical carcinogenesis: Concepts and clinical implications». J. Pathol. 208 (2): 152-64. doi:10.1002/path.1866. PMID 16362994.
Roden RB, Ling M, Wu TC (August 2004). «Vaccination to prevent and treat cervical cancer». Human pathology 35 (8): 971-82. doi:10.1016/j.humpath.2004.04.007. PMID 15297964.
Lowy DR, Schiller JT (May 2006). «Prophylactic human papillomavirus vaccines». The Journal of clinical investigation 116 (5): 1167-73. doi:10.1172/JCI28607. PMID 16670757.
D’Souza G, Kreimer AR, Viscidi R, et al. (May 2007). «Case-control study of human papillomavirus and oropharyngeal cancer». The New England journal of medicine 356 (19): 1944-56. doi:10.1056/NEJMoa065497. PMID 17494927.
Cottler L, Garvin EC, Callahan C (September 2006). «Condom use and the risk of HPV infection». The New England journal of medicine 355 (13): 1388-9; author reply 1389. doi:10.1056/NEJMc061933. PMID 17014039.
Palmer, T. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland : retrospective population study :
[անգլ.] / T. Palmer, L. Wallace, K. G. Pollock … [et al.] // BMJ : журн. — 2019. — Vol. 365. — L1161. — doi:10.1136/bmj.l1161. — PubMed. — PMC6446188.
McNeil C (April 2006). «Who invented the VLP cervical cancer vaccines?».Journal of the National Cancer Institute 98
(7):433. doi:10.1093/jnci/djj144. PMID 16595773.
Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004-08-20). «Against which human papillomavirus types shall we vaccinate and screen? The international perspective.».Int J Cancer 111 (2): 278-85. doi:10.1002/ijc.20244. PMID 15197783.
Harper DM, Franco EL, Wheeler CM, et al. (April 2006). «Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial». Lancet 367 (9518): 1247-55. doi:10.1016/S0140-6736(06)68439-0. PMID 16631880.
Cutts FT, Franceschi S, Goldie S et al(2007).«Humanpapillomavirus and HPV vaccines: a review». Bull World Health Organ 85 (9): 719-26. doi:10.2471/BLT.06.038414. PMID 18026629. [5].
Cutts FT, Franceschi S, Goldie S et al(2007).«Humanpapillomavirus and HPV vaccines: a review». Bull World Health Organ 85 (9): 719-26. doi:10.2471/BLT.06.038414. PMID 18026629. [5].
«FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus». FDA. 2006-06-08. [4]Արխիվացված 2009-05-12 Wayback Machine. Retrieved on 2007-02-04.